## Amendments to the Claims:

## This listing of claims replaces all prior versions of claims in the application

## 1. (currently amended) A co

A compound represented by the following formula:

or a pharmaceutically acceptable salt thereof wherein:

 $X^1 - X^3$  are independently C-or N;

X4 is CH-or N, wherein not more than two of X4 is N;

X<sup>6</sup> - X<sup>8</sup> are independently C-or N;

X9 is CH or N, wherein not more than two of X6 - X9 is N;

 $X^5$ -is N,  $R^5$ -is a lone pair, and  $X^{10}$  is CH, when the bond between  $X^5$  and  $X^{10}$  is a double bond; or

 $X^5$  is CH,  $R^5$  is H, and  $X^{10}$  is CH<sub>2</sub>, when the bond between  $X^5$  and  $X^{10}$  is a single bond; or

 $X^5$  is C,  $R^5$  is defined below, and  $X^{10}$  is CH, when the bond between  $X^5$  and  $X^{10}$  is a double bond;

R<sup>4</sup>-R<sup>3</sup>-and R<sup>6</sup>-R<sup>8</sup>-represent a lone pair or O when each respective X<sup>4</sup>-X<sup>3</sup>-and X<sup>6</sup>-X<sup>8</sup> is

when  $X^1 - X^3$  or  $X^6 - X^8$  is C, each respective  $R^1 - R^3$  and  $R^6 - R^8$  is independently selected from the group consisting of:

- a) H, substituted or unsubstituted C(1-8) alkyl, halogen, azido, cyano, nitro, or NR<sup>21</sup>R<sup>22</sup>, wherein R<sup>21</sup> represents H or C(1-8) alkyl, and R<sup>22</sup> represents H, substituted or unsubstituted C(1-8) alkylcarbonyl, substituted or unsubstituted arylcarbonyl, heterocycle, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted C(1-8) alkylaminocarbonyl, substituted or unsubstituted arylaminocarbonyl;
- b) OR<sup>23</sup>, wherein R<sup>23</sup> is H, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted arylcarbonyl;
- c) SR<sup>23</sup>, wherein R<sup>23</sup> is defined as in b);
- d) O(CH<sub>2</sub>)<sub>j</sub>-R<sup>24</sup>, O(CH<sub>2</sub>)<sub>j</sub>-O-R<sup>24</sup>, or O(CH<sub>2</sub>)<sub>j</sub>-S-R<sup>24</sup>, wherein j is an integer from 1 to 8, and R<sup>24</sup> is selected from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
- e) S(CH<sub>2</sub>)<sub>j</sub>R<sup>24</sup>, S(CH<sub>2</sub>)<sub>j</sub>-O-R<sup>24</sup>, or S(CH<sub>2</sub>)<sub>j</sub>-S-R<sup>24</sup>, wherein j and R<sup>24</sup> are defined as in d);
- f) C=C-R<sup>25</sup>, C=C-OR<sup>25</sup>, or C=C-CO<sub>2</sub>R<sup>25</sup>, wherein R<sup>25</sup> is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- g) CH=CH-R<sup>25</sup>, CH=CH-OR<sup>25</sup>, or CH=CH-CO<sub>2</sub>R<sup>25</sup>, having a stereochemistry of E or Z, and R<sup>25</sup> is defined as in f);
- h)  $C=C-NR^{25}R^{26}$  or  $C=CCONR^{25}R^{26}$ , wherein  $R^{25}$  is defined as in f), and  $R^{26}$  is defined as  $R^{25}$ , and  $R^{25}$  and  $R^{26}$  are selected independently;
- i) CH=CH-NR<sup>25</sup>R<sup>26</sup> or CH=CHCONR<sup>25</sup>R<sup>26</sup>, having a stereochemistry of E or Z, wherein R<sup>25</sup> and R<sup>26</sup> are independently defined as in h);
- j) (CH<sub>2</sub>)<sub>k</sub>R<sup>25</sup>, (CH<sub>2</sub>)<sub>k</sub>-COOR<sup>25</sup>, or (CH<sub>2</sub>)<sub>k</sub>-OR<sup>25</sup>, wherein k is an integer from 2 to 6 and R<sup>25</sup> is defined as in f);
- k) (CH<sub>2</sub>)<sub>k</sub>NR<sup>25</sup>R<sup>26</sup>, (CH<sub>2</sub>)<sub>k</sub>CONR<sup>25</sup>R<sup>26</sup>, wherein R<sup>25</sup> and R<sup>26</sup> are selected independently, and R<sup>25</sup> and R<sup>26</sup> are defined as R<sup>25</sup> in f); and
- CH<sub>2</sub>XR<sup>27</sup>, wherein X is O or S and R<sup>27</sup> is H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl;

R<sup>4</sup> is selected from the group consisting of:

m) H, substituted or unsubstituted C(1-8) alkyl; and

n)

wherein X=O, S, or NH, n=1 to 4; and wherein R<sup>51</sup> is H; R<sup>52</sup> and R<sup>53</sup> are independently chosen from the group consisting of H, substituted or unsubstituted C(1-8)alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R<sup>51</sup> and R<sup>52</sup> are combined to form a heteroalkyl, substituted heteroaryl, heteroaryl, or substituted heteroaryl ring system;

R<sup>5</sup> is selected from the group consisting of:

o) a lone pair when X5 is N; or

when X5 is C, R5 is selected from the group consisting of:

p) H, substituted and unsubstituted C(1-8) alkyl; and

q)

wherein X=O, S, or NH, n=1 to 4; and wherein R<sup>51</sup> is H; R<sup>52</sup> and R<sup>53</sup> are independently chosen from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R<sup>51</sup> and R<sup>52</sup> are combined to form a heteroalkyl, substituted heteroaryl, heteroaryl, or substituted heteroaryl ring system; or.

wherein when R<sup>1</sup>-R<sup>3</sup> and R<sup>5</sup>-R<sup>8</sup> are H, and R<sup>4</sup> is H or CH<sub>3</sub>, then at least one of X<sup>1</sup> — X<sup>4</sup> represents a ring member other than earbon.

- 2. (previously presented) A compound, according to claim 1, in which  $X^1 X^3$  are independently C.
- 3. (previously presented) A compound, according to claim 1, in which X<sup>4</sup> is CH.

4. (previously presented) A compound, according to claim 1, in which  $X^6 - X^8$  are independently C.

5. (currently amended) A compound, according to claim 1, in which X<sup>9</sup> is CH or N.

6. (previously presented) A compound, according to claim 1, in which  $X^5$  is C,  $X^{10}$  is CH and the bond between  $X^5$  and  $X^{10}$  is a double bond.

7. (withdrawn) A compound, according to claim 1, in which  $X^5$  is N,  $R^5$  is a lone pair,  $X^{10}$  is CH and the bond between  $X^5$  and  $X^{10}$  is a double bond.

8. (previously presented) A compound, according to claim 1, in which X<sup>5</sup> is CH, R<sup>5</sup> is H, X<sup>10</sup> is CH<sub>2</sub> and the bond between X<sup>5</sup> and X<sup>10</sup> is a single bond.

9. (currently amended) A compound having the following formula:

wherein  $X^5$  is C-or N, and  $X^1-X^3$ ,  $X^4$ ,  $X^6-X^8$ ,  $R^1-R^3$ ,  $R^4$ ,  $R^5$  and  $R^6-R^8$  are as defined in claim 1.

10. (previously presented) A compound having the following formula:

wherein X1-X3, X4, X6-X8, R1-R3, R4, R5 and R6-R8 are as defined in claim 1.

11. (withdrawn) A compound having the following formula:

wherein X1-X3, X4, X6-X8, R1-R3, R4, R5 and R6-R8 are as defined in claim 1.

12. (previously presented) A compound having the following formula:

wherein X1-X3, X4, X6-X8, R1-R3, R4, R5 and R6-R8 are as defined in claim 1.

13. (previously presented) A compound, according to claim 1, in which when  $X^1 - X^3$  or  $X^6 - X^8$  is C, each respective  $R^1 - R^3$  and  $R^6 - R^8$  is independently selected from the group consisting of:

- a) H, halogen;
- b) OR<sup>23</sup>, wherein R<sup>23</sup> is H, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted arylcarbonyl; and
- d) O(CH<sub>2</sub>)<sub>j</sub>-R<sup>24</sup>, O(CH<sub>2</sub>)<sub>j</sub>-O-R<sup>24</sup>, or O(CH<sub>2</sub>)<sub>j</sub>-S-R<sup>24</sup>, wherein j is an integer from 1 to 8, and R<sup>24</sup> is selected from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
- 14. (previously presented) A compound, according to claim 1, in which R<sup>4</sup> is selected from the group consisting of:
  - m) H, substituted or unsubstituted C(1-8) alkyl; and

n)

wherein X=O, S, or NH, n=2; and wherein R<sup>51</sup> is H; R<sup>52</sup> and R<sup>53</sup> are independently chosen from the group consisting of H, substituted or unsubstituted C(1-8)alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R<sup>51</sup> and R<sup>52</sup> are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.

15. (previously presented) A compound, according to claim 14, in which R<sup>4</sup> is selected from the group consisting of:

m) H, substituted or unsubstituted C(1-8) alkyl; and

n)

wherein X=S, n=2; and wherein R<sup>51</sup> is H; R<sup>52</sup> and R<sup>53</sup> are both H, or R<sup>51</sup> and R<sup>52</sup> are combined to form a heteroaryl ring system.

16. (previously presented) A compound, according to claim 15, in which R<sup>4</sup> is selected from the group consisting of: H, methyl, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>,

17. (withdrawn) A compound, according to claim 1, in which X<sup>5</sup> is N and R<sup>5</sup> is a lone pair.

18. (previously presented) A compound, according to claim 1, in which X<sup>5</sup> is C or CH, and R<sup>5</sup> is selected from the group consisting of:

p) H, substituted and unsubstituted C(1-8) alkyl; and

wherein X=S, n=2; and wherein R<sup>51</sup> is H; R<sup>52</sup> and R<sup>53</sup> are independently chosen from the group consisting of H, substituted or unsubstituted C(1-8) alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, or R<sup>51</sup> and R<sup>52</sup> are combined to form a heteroalkyl, substituted heteroalkyl, heteroaryl, or substituted heteroaryl ring system.

20. (currently amended) A compound, according to the following formula

selected from the group consisting of:

<del>Cpd.</del>	Bond between X <sup>5</sup> /X <sup>40</sup>	₽³	R <sup>60</sup>	₽²	X <sup>5</sup> /R <sup>5</sup>	X٩	X <sup>10</sup>
121	Double	Ħ	-OH	Ħ	€ <del>H</del>	CH	CH
124	Double	BnO	- <del>0H</del>	H	CH	CH	<del>CH</del>
<del>125</del>	Double	Ħ	-OH	Ħ	CMe	CH	#
<del>126</del>	Double	Ħ	-OH	BnO	CH _	<del>CH</del>	CH
127	Double	H	-OH	H	CH	CH	CMo
128	Double	H	<b>-</b> <del>OH</del>	Ħ	N.	C#	<del>CH</del>
120	Double	BnQ	-OH	Ħ	CMe	<del>CH</del>	CH
130	Double	H	-OH	Ħ	CH	H	CH
131	Double	BnO	- <del>O</del> H	Ħ	CH	CH	CMe
<del>132</del>	Double	H	- <del>0</del> H	Ę	CH	CH	CH
133	Double	H	-N(CH <sub>3</sub> ) <sub>3</sub>	H	CH	CH	CH
<del>136</del>	Double	BnO	<del>-N(CH<sub>s)2</sub></del>	Ħ	CH	CH	GH
137	Double	Ħ	-N(CH <sub>3</sub> ) <sub>2</sub>	Ħ	CMe	CH	CH
138	Double	Ħ	-N(CH <sub>3</sub> ) <sub>2</sub>	BnQ_	CH	CH	CH
139	Double	H	-N(CH <sub>3</sub> )₂	Ħ	CH	€Ħ	CMe
140	Double	H	-N(CH₃)₂	H	14	CH	CH
141	Double	BnQ	-N(CH <sub>3</sub> )₂	Ħ	CMe	CH_	CH
142	Double	Ħ	-N(CH <sub>3</sub> ) <sub>3</sub>	Ħ	CH	И	CH
143	Double	H	-SC(=NH)NH <sub>3</sub>	Ħ	CH	CH	CH
146	Double	H	-SC(=NH)NH <sub>2</sub>	Ħ	CMe	CH	CH
147	Double	Ħ	-SC(=NH)NH₂	BaO	€H .	CH	CH
148	Double	BnO	-SC(=NH)NH <sub>2</sub>	Ħ	CH	CH	CH
<del>149</del>	Double	BnO	-SC(=NH)NH₂	Ħ	CH	CMe	CH
<del>150</del>	Double	BnO	-SC(=NH)NH <sub>2</sub>	Ħ	CH	CH	CMe
151	Double	Ħ	-SC(=NH)NH <sub>2</sub>	Ħ	CH	CH	CMe
<del>152</del>	Double	H	-SC(=NH)NH2	Ħ	CH	N	CH
153	Double	MeO	-SC(=NH)NH2	H	<del>CH</del>	CH	CH
154	Double	Æ	-SC(=NH)NH <sub>2</sub>	Ħ	CH	CH	CH
<del>155</del>	Double	Ħ	-SC(=NH)NH2	E	<del>CH</del>	CH	CH
<del>156</del>	Double	Ħ	s N	H	CH	CH	CH
<del>150</del>	Single	Ħ	- <del>SC(=NH)NH₂</del>	H	<del>CH</del> ₂	CH	CH₂
160	Double	OCH <sub>2</sub> S ₽h	-SC(=NH)NH₂	H	CH	CH	CH
161	Double	Ħ	-N <sub>a</sub>	Ħ	CH	CH	CH
<del>162</del>	Double	H	-NH₂	H	CH	CH	€ <del>H</del>

21. (currently amended) A compound according to the following formula:

selected from the group consisting of:

	R <sup>4</sup>	R²	₽ <sup>50</sup>	R3	Example
†	Ħ	Ħ	<del>OH</del>	H	163
÷	Мө	H	OH	Ħ	164
i ;	Ħ	Ħ	OH OH	BnO	<del>165</del>
T ÷	Ħ	Ħ	SC(=NH)NH <sub>2</sub>	H	<del>166</del>
٦÷	Me	Ħ	SC(=NH)NH <sub>2</sub>	Ħ	167
<b>-</b>   ;	Me	H	SC(=NH)NH <sub>2</sub>	BnO	<del>168</del>
i ;	Me	Ħ	N(CH <sub>3</sub> ) <sub>2</sub>	H	<del>169</del>
÷	Мө	H	S N	H	<del>170</del>
;-an	Me	Ħ	N <sub>3</sub>	H	171
<b></b>	Me	H	NH <sub>2</sub>	Ħ	172

22.(previously presented) A composition comprising a compound, according to claim I, in combination with carrier.

23. (withdrawn) The composition, according to claim 22, further including a chemotherapeutic agent.

24. (withdrawn) The composition, according to claim 22, further including a cytokine.

- 25. (withdrawn) The composition, according to claim 22, further including antisense oligonucleotides.
- 26. (withdrawn) A method of treating an inflammatory disorder, the method comprising: administering to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, so as to treat the disorder.
- 27. (withdrawn) A method of treating cancer, the method comprising: administering to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, so as to treat the cancer.
- 28. (withdrawn) A method of treating a cell proliferative disorder, the method comprising: administering to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, so as to treat the disorder.
- 29. (withdrawn) A method of treating cancer, the method comprising: administering to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, in combination with another chemotherapeutic agent.
- 30. (withdrawn) Use of a compound or a composition, according to claim 1 or 22, so as to induce apoptosis in Jurkat cells.
- 31. (withdrawn) Use of a compound or a composition, according to claim 1 or 22, so as to induce apoptosis in cancer cell lines.
- 32. (withdrawn) The use, according to claim 31, in which the cancer cell lines are prostate cancer and breast cancer cell lines
- 33. (withdrawn) A method of treatment or prevention of a condition resulting from loss of growth and cellular differentiation control, the method comprising: administration to a subject in need thereof an effective amount of a compound or a composition, according to claim 1 or 22, so as to treat or prevent the condition.